DailyIQ
Last updatedUpdating…

ABT·Abbott Laboratories

$102.98
+0.37 (+0.36%)
After Hours
High
$104.16
Open
$104.06
Market Cap
177.12B
52W High
$135.00
Low
$101.69
P. Close
$102.98
P/E
32.65
52W Low
$81.97
Fwd P/E
16.92
DailyIQ Est.
$123.74
Inst. Ownership
36.3%
Short Interest
0.79%
Days to Cover
1.5
Div. Yield
2.41%
Next Ex-Div
~Oct 15
Div. Growth
12+ yrs
NewEarnings release, scored · filed Jul 16, 2026Guidance raised · tone +1.6 vs prior release · 78 lines scoredSee the breakdown
Technical Score (1D)
16
BEARISH
News Sentiment
63
BULLISH
On Oct 13, Abbott Laboratories advanced its bioelectronic medicine portfolio by developing closed‑loop neurostimulation systems that adjust therapy in real time based on neural signals. The technology builds on the company’s existing cardiac and diabetes device lines and targets chronic neurological conditions. This effort positions ABT as a key player in the emerging neurotechnology market, though it is not yet a transformative revenue driver. The company’s focus on integrating real‑time neural signal modulation enhances its chronic condition device portfolio. No other developments were reported for the company on that date.
LOW TARGET
$103 +0.0%
2 analysts
MEAN TARGET
$121 +17.2%
16 analysts
HIGH TARGET
$135 +31.1%
17 analysts
PRICE RANGE
$103.00 - $135.00
SB / B / H / S / SS
12/13/8/1/1
DAILYIQ EST.
$123.74 (+20.2%)
Sector
Healthcare
Industry
Medical Devices
Exchange
NYQ
Country
United States
Website
Symbol
ABT
Description
Abbott Laboratories is a global healthcare company focused on the discovery, development, and commercialization of a diverse portfolio of health products. The company operates across four main segments: established pharmaceuticals, diagnostics, nutritionals, and medical devices. Abbott's established pharmaceuticals division offers generic medications addressing a range of conditions, while its diagnostics segment provides laboratory systems and rapid testing solutions for infectious diseases and other health concerns. The company's nutritional products encompass pediatric and adult offerings, and its medical devices segment develops products for cardiovascular health, diabetes care, and neuromodulation. Founded in 1888, Abbott Laboratories is headquartered in North Chicago, Illinois.
Bought (1Y)
2,000 shares
$174K
Sold (1Y)
458,485 shares
$52.4M
Roman Michael F-
Award/Grant381 shares2026-09-30
Ahuja Nita-
Award/Grant318 shares2026-09-30
Conroy Kevin T-
Award/Grant318 shares2026-09-30
Gonzalez Patricia Paola-
Award/Grant333 shares2026-09-30
Stratton John G-
Award/Grant397 shares2026-09-30
77/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
56.4%
Net Margin
14.7%
Revenue CAGR
3.0%
Current Ratio
1.58x
Debt / Equity
0.25x
Return on Equity
12.5%
Earnings Summary
Abbott Laboratories, a long‑standing global healthcare company headquartered in North Chicago, Illinois, operates across pharmaceuticals, diagnostics, nutritionals, and medical devices, positioning it within the broader medical devices sector. In the most recent two quarters, Abbott reported revenue of $11.57 billion in Q1 2025 and $11.14 billion in Q2 2025, a slight decline from the $10.97 billion in Q4 2024, while EPS rose from $1.34 to $1.26, narrowly beating estimates in both periods. The company’s earnings trend shows a modest acceleration in EPS growth from $1.07 in Q1 2025 to $1.26 in Q2 2025, yet revenue growth has decelerated, reflecting a shift toward higher margin products. Historically, Abbott has maintained a consistent pattern of EPS beats, with 7 of the last 8 quarters exceeding analyst expectations, while revenue growth has remained positive but variable, often lagging behind EPS momentum. Recent news highlights include FDA approvals for heart‑failure monitoring and colorectal cancer screening, which could diversify revenue streams and influence future cash flows, though analysts note the impact may be incremental in the short term.

EPS

EstBeatMiss
$1.09$1.21$1.33$1.45$1.57Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$1.41 - -
Q2'26$1.42$1.31-7.9%
Q1'26$1.15$1.15+0.3%
Q4'25$1.51$1.50-0.8%
Q3'25$1.30$1.30+0.0%
Q2'25$1.26$1.26+0.3%

Revenue

EstBeatMiss
$10.7B$11.4B$12.1B$12.7B$13.4BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$13.1B - -
Q2'26$12.6B$12.6B-0.2%
Q1'26$11.0B$11.2B+1.5%
Q4'25$11.9B$11.5B-3.9%
Q3'25 - $11.4B -
Q2'25 - $11.1B -

Market Data

ABT Stock Snapshot

BEARISH16/100
$103.01+$0.03 (0.0%)
Market cap
177.12B
P/E ratio
32.6
Day range
$101.69 – $104.16
News sentiment
63/100 · Bullish
Analyst target
$120.72 (+17.2%)
Consensus
Buy · 35 analysts
52-week range+25.7% off low · -23.7% from high
$81.97$135.00
Price $103.01 DailyIQ Est. $123.74

The chart on ABT has not stabilised: price is in the lower half of its 52-week range and the trend is still down. Sector peers are worth watching - large caps in Healthcare tend to move together on rotation.

Reverse DCF

What growth is priced into ABT?

RICH

At today's price, Abbott Laboratories needs to grow free cash flow about 5.3% a year for the next 10 years to justify its valuation at a 7.14% cost of capital. Over its actual history it has compounded free cash flow at 1.8% a year, so the market is asking for 3.5 percentage points above its own delivered rate. On that basis ABT looks priced above what its own growth record supports.

Implied FCF growth
5.3%
Historical FCF CAGR
1.8%
Growth gap
+3.5 pts
Verdict
RICH
Discount rate (WACC)
7.14%
Beta
0.44

Behaviour On Record

What ABT's own history says about today's numbers

Realized volatility (21d)
21.5% 60th pct
Below its peak
-27.3%
vs 200-day average
-0.1%
Up days (1y)
47%

Abbott Laboratories is currently running 21.5% annualised volatility over the last 21 sessions. Measured against ABT's own 13 years of daily returns rather than a market-wide average, that is the 60th percentile — a little above its own norm, against a typical reading of 19.7%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

ABT is trading -27.3% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -17.2%, and the deepest was -31.9% in 2022. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits -0.1% from its 200-day moving average. Against every other day in its history, that gap ranks at the 32nd percentile — close to the gap it normally carries. Over the past year ABT closed higher on 47% of sessions, and it is currently 6 sessions into a rising streak.

On October specifically: over 14 years of records, ABT finished the month higher 8 of 14 times, with a median return of +1.8% and an average of +1.5%. Its strongest month historically has been July at +4.4% on average, its weakest September at -1.6%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: ABT has opened more than 2% away from the prior close in 42 of 3,267 sessions (1.3% of the time), with the largest gaps running +11.5% and -5.2%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, ABT moved an average of 1.9% in the session after earnings, closing higher 2 of those 3 times, with a median move of +1.6% and a largest of -2.0%.

All figures computed from 3,268 daily closes between 2013-10-15 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against ABT's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of ABT's sector?

Abbott Laboratories sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading). Within its narrower Medical Devices industry group, ABT ranks 2nd of 15 tracked industries, leading.

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
82
Industry rank
#2 of 15

Options Market

What is the options market pricing for ABT?

CallsPuts

For Abbott Laboratories's nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.48), with at-the-money implied volatility around 50.6%. The options market is pricing roughly a ±4.0% move by that expiry — a range of about $94.53–$102.47.

Put/call ratio (2026-10-16)
0.48
ATM implied volatility
50.6%
Total open interest
30,655
Expected move by 2026-10-16
±4.0% ($94.53–$102.47)

Analyst Rating Changes

Are analysts turning bullish or bearish on ABT?

Barclays most recently initiated coverage on Abbott Laboratories to Overweight on Oct 7, 2026 with a price target of $120. Over the last 90 days, coverage has run 2 upgrades against 0 downgrades, a net bullish lean.

Latest action
Barclays — Overweight
90-day upgrades
2
90-day downgrades
0
Net rating momentum
+2
DateFirmActionRatingPrice target
Oct 7, 2026BarclaysInitiatedOverweight$120
Oct 2, 2026Rothschild & CoUpgradeNeutral → Buy$119 → $127
Sep 8, 2026TD CowenReiteratedBuy$135
Aug 25, 2026TD CowenMaintainedBuy$115 → $135
Aug 21, 2026TD CowenMaintainedBuy$115 → $135
Aug 14, 2026CitigroupMaintainedBuy$112 → $125
Aug 13, 2026Wolfe ResearchUpgradePeer Perform → Outperform$130
Jul 28, 2026UBSMaintainedBuy$135 → $125
Jul 17, 2026CitigroupMaintainedBuy$108 → $112
Jul 17, 2026Piper SandlerReiteratedOverweight$115 → $118
Jul 17, 2026JP MorganMaintainedOverweight$110 → $120
Jul 17, 2026Wells FargoMaintainedOverweight$109 → $112

Earnings Release, Scored

What did Abbott Laboratories's latest earnings release say?

Filed Jul 16, 2026 · SEC Form 8-K, Exhibit 99

Guidance raised
Tone66.5/ 100+1.6 vs prior release
Hedging words0.40per 100 words+0.18 vs prior release
Tone, last 2 releasesScale 50–72

Most important lines

  1. 1

    – Abbott raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58

    Guidance raisedNew this quarter
  2. 2

    Abbott raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58.

    Guidance raisedNew this quarter
  3. 3

    Nutrition sales increased $127 million on a sequential basis compared to the first quarter of 2026.

    New this quarter

Peers & ETF holders

ABT peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

63/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Abbott Laboratories advanced its bioelectronic medicine portfolio by developing closed‑loop neurostimulation systems that adjust therapy in real time based on neural signals. The technology builds on the company’s existing cardiac and diabetes device lines, targeting chronic neurological conditions. Recognition of this effort positions ABT as a key player in the emerging neurotechnology market, though it is not yet a transformative revenue driver.
What did this article say?
Abbott (ABT) closed at $101.82, up 2.23% on the day, outperforming the S&P 500. The gain came as the market dipped overall, with the Nasdaq falling 0.44%. Investors noted that the company will report earnings on October 21, 2026, with analysts projecting a 9.23% increase in EPS to $1.42 and revenue growth of 13.52% to $12.91 billion for the quarter. The outlook suggests a modest positive bias for the stock as it approaches the earnings announcement.
What did this article say?
Abbott Laboratories (ABT) is highlighted for its diversified portfolio across diabetes care, medical devices, diagnostics, nutrition, and pharmaceuticals. The company’s long history of dividend increases positions it as an attractive option for income-focused investors, though its yield remains modest at about 2.5%. ABT’s competitive advantage stems from well-established brands, widespread product adoption, and a robust global distribution network that supports sustained earnings growth. The analysis suggests that while the dividend appeal is clear, the real value lies in ABT’s ability to maintain earnings momentum to support its share price.
What did this article say?
Abbott Laboratories announced the launch of Ensure Max Protein 3‑in‑1 Muscle Support, a protein powder that includes creatine and HMB. The product is NSF certified and aims to aid muscle building, recovery, and preservation for active consumers and athletes. The introduction broadens Abbott’s nutrition portfolio beyond its traditional devices and diagnostics, positioning the company in the performance‑focused supplement market. While the move diversifies Abbott’s offerings, it is not expected to materially shift the company’s overall financial outlook.
What did this article say?
Analyst projections indicate Abbott (ABT) could reach $210 per share by 2036, more than doubling its current price. The forecast relies on the company’s historical growth, with sales projected to rise from $21 billion in 2016 to $47 billion this year and earnings per share growing at 9.7% annually. Acquisitions have contributed to a nearly double‑digit compound annual earnings growth rate. The analysis frames this upside as a low‑risk, high‑quality dividend investment. The outlook is presented as a strong long‑term catalyst for the stock.
What did this article say?
Abbott Laboratories’ shares fell 23.1% over the past year, prompting a reassessment of the company’s valuation. New FDA approvals for heart‑failure monitoring and colorectal cancer screening could alter revenue mix and capital needs, potentially affecting future cash flows. A discounted‑cash‑flow analysis suggests the current $99.60 price may not be fully supported by projected earnings, raising concerns among investors.
What did this article say?
Analysts across 29 brokerage firms have given Abbott (ABT) an average rating of 1.41, falling between Strong Buy and Buy. The majority of recommendations—22 Strong Buys and 2 Buys—represent 75.9% and 6.9% of the total, respectively. The article discusses how such ratings can influence investor decisions and market price movements, while questioning the reliability of these consensus metrics. No new financial guidance or corporate developments were disclosed, leaving the impact on ABT’s valuation uncertain. The piece serves as a commentary on the weight of analyst sentiment rather than a direct corporate announcement.
What did this article say?
Citi reaffirmed Abbott Laboratories (ABT) as a leading medtech stock, citing the company’s recent earnings guidance lift and a strong continuous glucose monitoring (CGM) business. The investment bank highlighted CGM sales of $2 billion in Q1, up 7.5%, and projected a return to double‑digit growth in the second quarter. Abbott’s upgraded Buy rating from Rothschild Redburn and the potential for a re‑accelerated CGM trajectory underpin Citi’s bullish stance, positioning ABT for near‑term upside.
What did this article say?
Abbott Laboratories announced an exclusive U.S. partnership with Berry Street to integrate its Lingo glucose biowearable with live nutrition coaching. The collaboration will deliver insurance‑supported dietitian sessions that use real‑time glucose data to personalize lifestyle guidance for metabolic health. By adding a service layer to its existing hardware, Abbott aims to influence daily behavior and expand its footprint in connected health devices. The deal positions Abbott as a more comprehensive provider in the growing digital health market.

Technical Analysis

Real-time indicators across multiple timeframes

16
BEARISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $62.28B combined position · 14 adding, 11 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▲ Buy175,556,71610.18%$22.00B2026-01-29
BlackRock, Inc.▲ Buy152,563,4768.85%$13.84B2026-08-07
Geode Capital Management, LLC▲ Buy39,219,3372.27%$3.54B2026-08-12
Capital Research Global Investors▼ Sell36,908,9902.14%$3.35B2026-08-12
Morgan Stanley▼ Sell26,611,3151.54%$2.41B2026-08-13
Norges Bank▼ Sell23,354,9111.35%$2.12B2026-08-12
Northern Trust Corp▼ Sell18,273,3011.06%$1.66B2026-08-13
Bank of America Corp▼ Sell17,672,5431.02%$1.60B2026-08-14
Goldman Sachs Group Inc▲ Buy16,760,0700.97%$1.52B2026-08-14
JPMorgan Chase & Co▼ Sell15,095,8980.88%$1.40B2026-08-12
Wells Fargo & Company▼ Sell15,177,3170.88%$1.38B2026-08-14
FMR LLC (Fidelity)▲ Buy13,423,0800.78%$1.22B2026-08-13
Janus Henderson Group plc▲ Buy8,092,9170.47%$830.86M2026-05-18
Invesco Ltd.▼ Sell8,817,2400.51%$800.08M2026-08-14
Citadel Advisors LLC▲ Buy8,597,2270.50%$780.11M2026-09-02
Wellington Management Group LLP▼ Sell8,304,7090.48%$753.57M2026-08-14
Two Sigma Investments, LP▲ Buy8,126,3150.47%$737.38M2026-08-14
Marshall Wace, LLP▲ Buy5,542,4380.32%$502.92M2026-08-13
AQR Capital Management LLC▲ Buy4,193,0580.24%$380.48M2026-08-14
Millennium Management LLC▲ Buy3,599,9940.21%$326.66M2026-08-14
AllianceBernstein L.P.▼ Sell2,999,0500.17%$307.91M2026-08-14
Citigroup Inc▲ Buy2,621,3980.15%$237.87M2026-08-03
Neuberger Berman Group LLC▼ Sell2,558,1110.15%$232.26M2026-08-13
Adage Capital Partners GP, L.L.C.▲ Buy2,332,1150.14%$211.62M2026-08-14
Point72 Asset Management, L.P.▲ New1,551,9290.09%$140.82M2026-08-14
Q2 2026 flow:31.26M sh bought ($2.84B)56.51M sh sold ($5.21B)net -25.25M sh (−$2.37B)
Congressional Trading Activity
25 disclosed trades · ~$265.5K est. traded value · 8 buys, 16 sells
MemberChamberStateTypeAmountTradedFiled
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-09-182026-10-12
Richard Dean Dr McCormickHouseGA06▼ Sell$1K - $15K2026-07-302026-08-14
Mike KellyHousePA16▼ Sell$1K - $15K2026-07-172026-08-12
Richard W. AllenHouseGA12▼ Sell$15K - $50K2026-07-142026-08-18
Rick LarsenHouseWA02▼ Sell$1K - $15K2026-07-082026-07-12
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-06-162026-07-02
Richard Dean Dr McCormickHouseGA06▲ Buy$1K - $15K2026-06-122026-07-09
Josh GottheimerHouseNJ05▼ Sell$1K - $15K2026-05-272026-06-03
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2026-05-152026-06-08
Julie JohnsonHouseTX32▼ Sell$1K - $15K2026-05-122026-06-12
Richard W. AllenHouseGA12▼ Sell$15K - $50K2026-04-162026-06-05
Alan ArmstrongSenateOK▼ Sell$15K - $50K2026-03-272026-07-21
Laura FriedmanHouseCA30↔ Exchange$1K - $15K2026-03-242026-04-17
Richard Dean Dr McCormickHouseGA06▲ Buy$1K - $15K2026-03-192026-04-07
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2026-02-102026-03-09
Thomas H. KeanHouseNJ07▲ Buy$1K - $15K2026-01-292026-02-19
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2025-12-192026-01-12
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-12-182026-01-15
Julia LetlowHouseLA05▼ Sell$1K - $15K2025-12-082026-01-13
Byron DonaldsHouseFL19▼ Sell$1K - $15K2025-12-042026-01-07
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-11-182025-12-15
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-11-132025-12-11
Richard Dean Dr McCormickHouseGA06▲ Buy$1K - $15K2025-11-052025-12-09
Rick LarsenHouseWA02▲ Buy$1K - $15K2025-10-062025-10-16
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-08-142025-09-11